Back to top
more

Patterson Companies (PDCO)

(Delayed Data from NSDQ)

$26.18 USD

26.18
471,486

+0.21 (0.81%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $26.20 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Patterson Companies (PDCO) Q4 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter 2022 results benefit from strength in the Dental and Animal Health segments.

Patterson Cos. (PDCO) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Patterson Cos. (PDCO) delivered earnings and revenue surprises of 26.79% and 1.71%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Patterson Cos. (PDCO) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Patterson Cos. (PDCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.

What's in Store for Patterson Companies' (PDCO) Q4 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.

Veeva Systems (VEEV) Unveils New Study Training Application

by Zacks Equity Research

Veeva Systems' (VEEV) new clinical study training application will address the demands and complexities involved in present-day trials.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

PerkinElmer (PKI) Unveils New NGS System to Aid Genomic Analysis

by Zacks Equity Research

PerkinElmer's (PKI) introduction of the RUO BioQule NGS System is a cost-effective system that can bring improvements in genomic analysis.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Here's Why You Should Retain ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies. However, limited commercial expertise is a woe.

Cardinal Health (CAH) to Extend Warehouse Footing With New Center

by Zacks Equity Research

Cardinal Health's (CAH) new distribution center to support the company's at-Home Solutions business.

BD's (BDX) Latest Product to Transform Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting as well as provide answers to previously unthinkable questions.

Accuray's (ARAY) New Tie-Up to Augment Treatment Planning

by Zacks Equity Research

Accuray (ARAY) partners with Limbus AI to enhance the treatment planning process and patient care.

The Cooper Companies (COO) Q2 Earnings Lag Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of -4.99% and 1.35%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

DexCom (DXCM) to Boost Diabetes Management With New Coverage

by Zacks Equity Research

DexCom's (DXCM) G6 CGM System gets public coverage through Prince Edward Island's Diabetes Glucose Sensor Program, which can aid in effective diabetes management.

    Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

    Here's Why You Should Retain QuidelOrtho (QDEL) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

    Here's Why Investors Should Retain Cerner (CERN) Stock Now

    by Zacks Equity Research

    Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

    Stryker's (SYK) Q Guidance System Receives FDA Approval

    by Zacks Equity Research

    Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.

    PDCO or CNMD: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    PDCO vs. CNMD: Which Stock Is the Better Value Option?

    Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

    by Zacks Equity Research

    Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

    Abbott (ABT) to Commence Limited Release of EleCare Soon

    by Zacks Equity Research

    Abbott's (ABT) release of limited quantities of EleCare branded specialty formulas to be free of charge to children in need.